e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 which is in preclinical trial to treat metabolic dysfunction-associated steatohepatitis; ETX-407 which is in preclinical trial for the treatment of dry age-related macular degeneration; and ETX-148 which is in preclinical trial for the treatment of bleeding disorders. In addition, the company develops ETX-291 which is in preclinical trial to treat cardiometabolic disease; and ETX-258 which is in preclinical trial for heart failure treatment. e-therapeutics plc was incorporated in 2001 and is based in London, the United Kingdom.
Metrics to compare | ETXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETXPPeersSector | |
---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |